Nuclear Medicine: JRC Alpha-immunotherapy treatment for bladder cancer shares 2008 Marie-Curie Award
A joint study involving JRC scientists Frank Bruchertseifer and Alfred Morgenstern from the Institute for Transuranium Elements (ITU) and collaborators from Klinikum Rechts der Isar (KRDI) in Munich has won the 2008 Marie Curie Award of the European Association of Nuclear Medicine.
The JRC scientists are part of the ITU's Alpha-immunotherapy team and the award is for a study on the treatment of bladder carcinoma carried out jointly with KRDI, a section of the Technical University of Munich. In the study a novel therapeutic method was developed using the alpha emitter Bismuth-213.
Bladder carcinoma is a common urological tumour, responsible for about 3.5% of cancer deaths in Europe. In the award winning study mice were tested in a manner that closely resembles a procedure applicable to humans. Treatment with Bi-213 has shown excellent response rates and significantly increased survival of treated animals compared to those that received conventional chemotherapy or no treatment. The promising results should lead to clinical tests on cancer patients in the near future.
The president of the EANM (European Association of Nuclear Medicine) presented the prestigious Marie Curie prize to Birgit Pfost, who accepted the award as principle author of the report and representative of the KRDI-ITU team, at the highlights session of EANM's annual meeting in Munich on 15 October, 2008. The prize carries a value of €3,000.